CA2828043A1 - Vaincre la resistance a des inhibiteurs de la voie erbb - Google Patents
Vaincre la resistance a des inhibiteurs de la voie erbb Download PDFInfo
- Publication number
- CA2828043A1 CA2828043A1 CA2828043A CA2828043A CA2828043A1 CA 2828043 A1 CA2828043 A1 CA 2828043A1 CA 2828043 A CA2828043 A CA 2828043A CA 2828043 A CA2828043 A CA 2828043A CA 2828043 A1 CA2828043 A1 CA 2828043A1
- Authority
- CA
- Canada
- Prior art keywords
- inhibitor
- erbb3
- egfr
- tumor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452974P | 2011-03-15 | 2011-03-15 | |
US201161452976P | 2011-03-15 | 2011-03-15 | |
US61/452,974 | 2011-03-15 | ||
US61/452,976 | 2011-03-15 | ||
PCT/US2012/029292 WO2012125864A2 (fr) | 2011-03-15 | 2012-03-15 | Vaincre la résistance à des inhibiteurs de la voie erbb |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2828043A1 true CA2828043A1 (fr) | 2012-09-20 |
Family
ID=45953230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2828043A Abandoned CA2828043A1 (fr) | 2011-03-15 | 2012-03-15 | Vaincre la resistance a des inhibiteurs de la voie erbb |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150231238A1 (fr) |
EP (2) | EP2815765A1 (fr) |
JP (1) | JP2014509593A (fr) |
KR (1) | KR20140023921A (fr) |
CN (1) | CN103429262A (fr) |
AU (1) | AU2012229062A1 (fr) |
BR (1) | BR112013022887A2 (fr) |
CA (1) | CA2828043A1 (fr) |
EA (1) | EA201301025A1 (fr) |
IL (1) | IL228393A0 (fr) |
MX (1) | MX2013010444A (fr) |
SG (1) | SG192775A1 (fr) |
WO (1) | WO2012125864A2 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2647388A1 (fr) * | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Anticorps dirigés contre l'ERBB3 et leurs utilisations |
AU2011224186C1 (en) | 2010-03-11 | 2015-04-02 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
JP6169085B2 (ja) * | 2011-10-06 | 2017-07-26 | アベオ ファーマシューティカルズ, インコーポレイテッド | 抗erbb3抗体に対する腫瘍応答の推定 |
CN104093743B (zh) | 2011-11-23 | 2018-04-24 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
CA2862306C (fr) * | 2012-01-19 | 2019-08-27 | Duke University | Vaccins diriges contre des antigenes impliques dans la resistance a un traitement et leurs methodes d'utilisation |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
US11305012B2 (en) * | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
US10519247B2 (en) | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
WO2015100459A2 (fr) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies |
NZ724013A (en) | 2014-02-28 | 2019-11-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
JP6967853B2 (ja) * | 2014-02-28 | 2021-11-17 | メルス ナムローゼ フェンノートシャップ | ErbB−2およびErbB−3に結合する抗体 |
US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
CA2944892A1 (fr) * | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anticorps bispecifiques anti her3/her2 se liant a l'epingle a cheveux beta de her3 et du domaine ii de her2 |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
CA2954278A1 (fr) | 2014-07-07 | 2016-01-14 | Duke University | Vaccins contre un isoforme oncogene d'her2 (erbb2) et leurs methodes d'utilisation |
CA2954279C (fr) | 2014-07-07 | 2023-11-14 | Duke University | Vaccins diriges contre une isoforme oncogene d'esr1 et leurs methodes d'utilisation |
JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | チロシンキナーゼ阻害薬(tki)に耐性のがんを処置するための組成物および方法 |
US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
MA45420A (fr) * | 2015-04-17 | 2019-05-01 | Merrimack Pharmaceuticals Inc | Traitements combinés avec seribantumab |
EP3288963B1 (fr) * | 2015-05-01 | 2020-12-23 | Wo, Andrew Man Chung | Polypeptide à domaine c-terminal pink1 et leurs méthodes d'utilisation dans le traitement du cancer |
US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
WO2017035482A1 (fr) * | 2015-08-27 | 2017-03-02 | Merrimack Pharmaceuticals, Inc | Polythérapies pour le traitement de cancers positifs à l'héréguline |
EA201890866A1 (ru) | 2015-10-23 | 2018-09-28 | Мерус Н.В. | Связывающие молекулы, которые ингибируют рост рака |
EP3176183A1 (fr) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions et procédés pour traiter un cancer non résistant à un inhibiteur de la tyrosine kinase (tki) |
US11253580B2 (en) | 2016-01-07 | 2022-02-22 | Duke University | Cancer vaccines and methods of delivery |
US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
JP2020511993A (ja) | 2017-03-31 | 2020-04-23 | メルス ナムローゼ フェンノートシャップ | NRG1融合遺伝子を有する細胞の処置における使用のためのErbB−2及びErbB3結合二重特異性抗体 |
CN111094351B (zh) | 2017-08-09 | 2024-07-12 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
WO2019088348A1 (fr) * | 2017-11-06 | 2019-05-09 | 한국과학기술원 | Agent de traitement du cancer résistant aux inhibiteurs d'egfr |
KR20220103954A (ko) * | 2019-10-24 | 2022-07-25 | 메뤼스 엔.페. | Her2 및 her3 양성암인 대상의 치료 수단 및 치료 방법 |
AR127893A1 (es) * | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
EP1283053A1 (fr) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibiteurs de l'activité de HER3 |
CN100424175C (zh) | 2002-03-26 | 2008-10-08 | 上海泽生科技开发有限公司 | ErbB-3 用于肿瘤治疗的方法和组合物 |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
EP2647388A1 (fr) | 2007-02-16 | 2013-10-09 | Merrimack Pharmaceuticals, Inc. | Anticorps dirigés contre l'ERBB3 et leurs utilisations |
CN101675075B (zh) | 2007-03-01 | 2014-06-18 | 西福根有限公司 | 重组抗表皮生长因子受体抗体组合物 |
EP2155877A2 (fr) | 2007-05-11 | 2010-02-24 | Santaris Pharma A/S | Composés antagonistes de l'arn modulant le her3 |
MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
EP2425009A4 (fr) | 2009-04-29 | 2013-01-23 | Trellis Bioscience Llc | Anticorps ameliores immunoreactifs avec her3 couple hereguline |
MY161909A (en) | 2009-12-22 | 2017-05-15 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
EP2635605B1 (fr) * | 2010-11-01 | 2018-07-25 | Symphogen A/S | Anticorps anti-her3 et compositions |
CA2828099A1 (fr) * | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Polytherapies comprenant des agents anti-erbb3 |
-
2012
- 2012-03-15 CA CA2828043A patent/CA2828043A1/fr not_active Abandoned
- 2012-03-15 SG SG2013061791A patent/SG192775A1/en unknown
- 2012-03-15 WO PCT/US2012/029292 patent/WO2012125864A2/fr active Application Filing
- 2012-03-15 US US14/004,848 patent/US20150231238A1/en not_active Abandoned
- 2012-03-15 KR KR1020137026522A patent/KR20140023921A/ko not_active Application Discontinuation
- 2012-03-15 AU AU2012229062A patent/AU2012229062A1/en not_active Abandoned
- 2012-03-15 CN CN201280011820XA patent/CN103429262A/zh active Pending
- 2012-03-15 EA EA201301025A patent/EA201301025A1/ru unknown
- 2012-03-15 JP JP2013558187A patent/JP2014509593A/ja not_active Withdrawn
- 2012-03-15 BR BR112013022887A patent/BR112013022887A2/pt not_active IP Right Cessation
- 2012-03-15 EP EP14166702.2A patent/EP2815765A1/fr not_active Withdrawn
- 2012-03-15 EP EP12714108.3A patent/EP2686015A2/fr not_active Withdrawn
- 2012-03-15 MX MX2013010444A patent/MX2013010444A/es unknown
-
2013
- 2013-09-12 IL IL228393A patent/IL228393A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2012229062A1 (en) | 2013-04-11 |
MX2013010444A (es) | 2014-03-21 |
WO2012125864A2 (fr) | 2012-09-20 |
EA201301025A1 (ru) | 2014-01-30 |
IL228393A0 (en) | 2013-12-31 |
CN103429262A (zh) | 2013-12-04 |
JP2014509593A (ja) | 2014-04-21 |
US20150231238A1 (en) | 2015-08-20 |
KR20140023921A (ko) | 2014-02-27 |
EP2815765A1 (fr) | 2014-12-24 |
EP2686015A2 (fr) | 2014-01-22 |
SG192775A1 (en) | 2013-09-30 |
BR112013022887A2 (pt) | 2016-12-06 |
WO2012125864A3 (fr) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2815765A1 (fr) | Surmonter la résistance aux inhibiteurs de la voie ERBB | |
US9518130B2 (en) | Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
US9822170B2 (en) | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer | |
CA2828075A1 (fr) | Utilisation d'inhibiteurs des recepteurs de la famille egfr dans le traitement de cancers du sein refractaires aux hormones | |
MX2011005383A (es) | Terapia anti-angiogenesis para el tratamiento del cancer de mama. | |
US20140056898A1 (en) | Combination therapies comprising anti-erbb3 agents | |
US20180066065A1 (en) | Combination therapies comprising anti-erbb3 agents | |
WO2013023043A2 (fr) | Traitement de tumeurs solides avancées à l'aide d'une combinaison d'une immunothérapie anti-erbb3 et d'une chimiothérapie sélectionnée | |
RU2576027C2 (ru) | Антиангиогенная терапия для лечения ранее подвергавшегося лечению рака молочной железы | |
CA3233721A1 (fr) | Methodes de traitement du cancer et compositions pharmaceutiques associees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20170315 |